Merck开始3BVirginia工厂 推动美国毒品生产 创造了数千个就业机会 Merck starts $3B Virginia plant to boost U.S. drug production, creating thousands of jobs.

Merck已开始在弗吉尼亚州埃尔克顿建造一个价值30亿美元的制药设施,这是2025年为扩大国内制造业和研发而启动的700亿美元的美国投资计划的一部分。 Merck has begun construction on a $3 billion pharmaceutical facility in Elkton, Virginia, part of a $70 billion U.S. investment plan launched in 2025 to expand domestic manufacturing and R&D. 预计将于2030年开放的400 000平方英尺场地将生产疫苗、活性药物原料和小型及大型分子药品,创造500多个全职工作和多达8 000个建筑职位。 The 400,000-square-foot site, expected to open in 2030, will produce vaccines, active pharmaceutical ingredients, and small- and large-molecule drugs, creating over 500 full-time jobs and up to 8,000 construction positions. 该项目是默克公司今年在美国的几个主要扩张项目之一，包括北卡罗来纳州、特拉华州和堪萨斯州的工厂，总共创造了数千个就业机会。 The project is one of several major U.S. expansions by Merck this year, including sites in North Carolina, Delaware, and Kansas, collectively generating thousands of jobs. 这一举动与联邦在拟议进口药品关税的推动下为增加国内生产所做的努力相一致,尽管这些政策的时限仍然不确定。 The move aligns with federal efforts to boost domestic production, spurred by proposed tariffs on imported drugs, though the timeline for those policies remains uncertain.